As of 2026-03-20, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 91.52 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 16.5x | 13.9x |
| Forward P/E multiples | 17.8x - 21.6x | 19.8x |
| Fair Price | (8.98) - (8.31) | (8.49) |
| Upside | -380.7% - -359.6% | -365.4% |
| Date | EV/EBITDA |